Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06128733 · ClinicalTrials.gov registry record · Phase 1
Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
A Phase 1 study of Healthy Volunteers and Meningococcal Immunisation, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,215
- Enrollment target
- 20
- Study locations
NCT06128733 is a Phase 1 study of Healthy Volunteers and Meningococcal Immunisation that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 1,215 participants, above the 477-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (155% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06128733, a Phase 1 study of Healthy Volunteers and Meningococcal Immunisation, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,215 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents. The study duration will be up to 12 months for all participants.
Conditions Studied
Interventions
- BIOLOGICAL Pentavalent Meningococcal ABCYW vaccine
- BIOLOGICAL MenACYW conjugate vaccine
- BIOLOGICAL Meningococcal group B vaccine
Study Locations (20)
Florida
- Accel Clinical Research-Deland Clinical Research Unit- Site Number : 8400081 - DeLand
- SIMEDHealth, LLC- Site Number : 8400045 - Gainesville
- Accel Research Sites-St. Petersburg-Largo- Site Number : 8400082 - Largo
- South Florida Research Organization Site Number : 8400086 - Medley
- Life Arc Research-Miami Site Number : 8400094 - Miami
- Charisma Medical and Research center Site Number : 8400097 - Miami Lakes
- Accel Research - Nona Pediatric Center Site Number : 8400079 - Orlando
- Ormond Beach Clinical Research- Site Number : 8400073 - Ormond Beach
- Palm Harbor Dermatology- Site Number : 8400030 - Tampa
- PAS Research Site Number : 8400032 - Tampa
- VICIS Clinical Research-Tampa Site Number : 8400065 - Tampa
California
- Smart Cures Clinical Research Site Number : 8400072 - Anaheim
- Hope Clinical Research, LLC- Site Number : 8400001 - Canoga Park
- Apex Research Group Site Number : 8400071 - Fair Oaks
Alabama
- Accel Research Site - Birmingham Clinical Research Unit- Site Number : 8400080 - Birmingham
- Lakeview Clinical Research Site Number : 8400029 - Guntersville
Arizona
- Alliance for Multispecialty Research- Phoenix- Site Number : 8400056 - Tempe
Arkansas
- Harrisburg Family Medical Center Site Number : 8400070 - Harrisburg
District of Columbia
- Velocity Clinical Research-Washington DC Site Number : 8400102 - Washington D.C.
Idaho
- Leavitt Clinical Research-Idaho Falls- Site Number : 8400075 - Idaho Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,215 participants |
| Start Date | 2023-10-31 |
| Est. Completion | 2025-08-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06128733
The ClinicalTrials.gov registry entry for NCT06128733 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1,215 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 477-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (155% higher). The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Pentavalent Meningococcal ABCYW vaccine is the first listed.
NCT06128733 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06128733 about?
NCT06128733 is a clinical study titled "Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents". The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents. The study duration will be up to 12 months for all participants.
What is the current status of trial NCT06128733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,215 participants. The study started on 2023-10-31. Estimated completion is 2025-08-27.
What conditions does trial NCT06128733 study?
This clinical trial studies the following conditions: Healthy Volunteers, Meningococcal Immunisation.
What interventions are being tested in trial NCT06128733?
The interventions under investigation include: Pentavalent Meningococcal ABCYW vaccine (BIOLOGICAL), MenACYW conjugate vaccine (BIOLOGICAL), Meningococcal group B vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06128733?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06128733 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.